Moreover, ADAR1-mediated A-to-I editing influences cellular responses to DNA-damaging agents: knockdown of ADAR1 significantly reduces cell viability following cisplatin treatment in cholangiocarcinoma HuCCT1 and RBE cell lines (Liu et al., 2024). Here, ADAR is linked to cholangiocarcinoma.